The acquisition of the Philadelphia (Ph) chromosome (or BCR-ABL translocation) represents a detrimental pathophysiological event in humans. The activated tyrosine kinases, which are produced by this translocation, are associated with fatal hematological malignancies. The initial molecular dissection of BCR-ABL has linked the expression of this constitutively activated kinase with enhanced genomic instability. We directly evaluated the consequence of BCR-ABL expression on genomic instability using the Big Blue in vivo mutagenesis mouse system. We report that the expression of BCR-ABL in both spleens and kidneys confers a mutator phenotype represented by a statistically significant elevation in mutant frequencies.
Introduction
The etiological role of BCR-ABL-activated kinases in the pathogenesis of human leukemias is clearly demonstrated in a number of transgenic mouse models that express P190 1 or P210 2,3 BCR-ABL, as well as in lethally irradiated mice which were reconstituted by transplantation with stem cells expressing bcr-abl gene constructs. 4 The molecular basis of BCR-ABLinduced oncogenesis is not well understood. BCR-ABL is implicated in the perturbation of a number of signal transduction pathways that may lead to the activation of Ras, 5 alteration of cellular adherence to extracellular matrix, 6 and the inhibition of apoptosis. 7 The expression of BCR-ABL both in vitro and in vivo is associated with genomic instability. This is clinically demonstrated by secondary nonrandom cytogenetic and molecular genetic abnormalities associated with blast crisis transition in chronic myelogenous leukemia (CML) patients. 8 Also, nonrandom chromosomal changes mimicking those encountered in blast crisis transition in CML are observed during later stages of leukemia in P190BCR-ABL transgenic mice, 9 as well as in a myeloblastic cell line transformed to IL-3 independence by P210BCR-ABL expression. 10 We have previously shown that aberrant cell cycle and apoptotic responses are not responsible for the inherent genomic instability characteristic of BCR-ABL expression (manuscript submitted for publication). These experiments utilized the P190BCR-ABL leukemia mouse model in a stage prior to the development of disease and when the BCR-ABL activated kinase is expressed in most tissues tested.
1 During this pre-leukemic (PL) stage, the effect of BCR-ABL expression on biological processes safeguarding genomic stability can be studied prior to overt transformation due to disease progression. We concluded that unlike results obtained in cell lines expressing BCR-ABL [10] [11] [12] loss of sensitivity to DNA damage, in this animal model, might define a late event in BCR-ABL oncogenesis. We hypothesized that the BCR-ABLinduced genomic instability observed both in vivo and in vitro might be caused by the abrogation of DNA repair and/or replication mechanisms. In this study we directly investigated genomic instability in P190BCR-ABL transgenic mice by measuring mutant frequencies as a result of the expression of the BCR-ABL kinase.
Materials and methods

Mice and lambda () phage production
The Big Blue (BB) (C57BL/6) (Stratagene, La Jolla, CA, USA) transgenic mouse system is a reliable means to determine mutant frequencies in vivo in the context of normal physiological, metabolic, and DNA repair mechanisms. 13 This system employs a chromosomally-integrated bacteriophage shuttle vector (LIZ) that contains the bacterial lacI gene as a target for mutation and ␣lacZ as a reporter gene. Every cell in the Big Blue mouse contains multiple copies of the chromosomally integrated bacteriophage shuttle vector (LIZ). P190BCR-ABL (F 1 C57BLxCBA)/BB double heterozygotes were generated allowing the expression of BCR-ABL in the presence of the Big Blue mutation detection system. To assay BCR-ABL induced mutations on lacI sequences, genomic DNA was extracted from PL P190BCR-ABL/BB tissues (spleen and kidney). DNA extraction was performed using RecoverEase DNA isolation kit (Stratagene), following the manufacturer's protocol. Genomic DNA was then used to recover the phage vector containing the lacI and ␣lacZ sequences. This was done by shuttling the phage vector, from its origin in mammalian DNA, to a bacterial Escherichia (E.) coli host. Using a Transpack lambda packaging extract (Stratagene), the shuttle vector was excised from mammalian DNA and packaged into virulent bacteriophages. These viable bacteriophages were then used to infect SCS-8 E. coli cells. In parallel, mice with a similar genetic background to P190BCR-ABL transgenics (F 1 C57BL6xCBA) (Jackson, Bar Harbor, ME, USA) were crossed to BB mice and DNA was extracted from the same organs and processed in a similar fashion to DNA extracted from PL P190BCR-ABL/BB mice.
Mutant frequency determination and sequencing mutant plaques
Bacteriophages carrying mutations in lacI were screened by using ␣-complementation in E. coli growing in the presence of the chromogenic analog 5-bromo-4-chloro-3-indol-␤-galactopyranoside (X-gal). Bacteriophages carrying mutations in lacI coding sequences will express ␣LacZ from the shuttle Leukemia vector. ␣LacZ will combine with the remaining part of LacZ in SCS-8 cells (SCS-8 cells are ␣lacZ − ) to give a complete LacZ enzyme capable of cleaving X-gal to generate a blue color. Mutant frequencies were calculated as ratios of mutant (blue) plaques to the total number of plated plaques for each tissue. Twenty-two representative mutants from spleens and kidneys of PL P190BCR-ABL/BB were grown and sequenced. Mutant bacteriophages were grown using the Wizard Lambda Preps DNA Purification System (Promega, Madison, WI, USA), following the manufacturer's protocol. One microliter of the grown phage DNA was used as a template to amplify a 1338 bp region containing the lacI gene and the lacZ operator. Two upstream and four downstream primers (Stratagene) were used to circumvent failed amplifications due to mutations in the primer region.
The entire lacI gene and the lacZ operator were sequenced by cycle sequencing using ABI automated sequencer (373A Applied Biosystems, Perkin Elmer, MD, USA). Five primers reading in the 5Ј-3Ј direction (1A, 3, 4, 6, and 7) were initially used with Dye Terminator Cycle Sequencing kit (Perkin Elmer, Gaithersburg, MD, USA). Mutations were then confirmed by sequencing in the opposite direction with one of the 3Ј-5Ј primers (14, 13A, 11A, and 9A). Primers used and conditions were as suggested by the manufacturer of the Big Blue transgenic system (Stratagene). Readable chromatograms were typically 300-350 bp in length per each primer run. Different chromatograms of the same mutant were combined, aligned, and compared to wild-type lacI sequences using the MacVector sequence analysis software. The mutational spectrum in PL P190BCR-ABL/BB was grouped into four categories: transitions at CpG, transitions not at CpG, transversions at CpG, and transversions not at CpG. The obtained mutation profile was compared to a list of reported mutations in the Big Blue lacI gene compiled in lacI database and software (MutaBase Software, Cariello and Gorelick 22 ) to determine mutations specifically induced by BCR-ABL. The mutation spectrum observed in P190BCR-ABL/BB mice was also compared to lacI spontaneous mutations in the Big Blue transgenic mouse system compiled in lacI database software (MutaBase Software, Cariello and Gorelick 22 ).
Statistical analysis
Mutant frequencies in spleens and kidneys of P190Bcr-abl/BB mice were compared to normal/BB mice by determining P values calculated using the Student's t-test. Data sets of different tissues were shown to exhibit a normal distribution by using the Kolmogorov-Smirnov normality test (SigmaStat, SPSS Inc, Chicago, IL, USA). For mutational spectrum comparison an extension of Fisher's exact hypergeometric test in its computer intensive Monte Carlo implementation was used.
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Results and discussion
Mutant frequencies were compared in spleens and kidneys from PL P190BCR-ABL/BB and normal/BB mice. Mice from both groups were maintained under identical living and diet conditions. Tissues for mutant frequency studies were obtained from young (4-6 weeks) PL P190BCR-ABL/BB and normal/BB mice and were processed in parallel. Mice were confirmed to be in the pre-leukemic phase by examining bone marrow and peripheral blood smears, collected from each, for the presence of leukemic blast cells (data not shown). In addition, differential analysis of peripheral cell blood counts (CBA) was performed to exclude the presence of hematological abnormalities. A total of 786 880 plaques from six kidneys (three PL P190BCR-ABL/BB and three normal/BB mice) and 1 043 721 from eight spleens (four PL P190BCR-ABL/BB and four normal/BB mice) were analyzed for the presence of blue mutant plaques (Table 1) . Blue mutant plaques were confirmed by replating twice on SCS-8 bacterial lawns grown in the presence of X-gal. One hundred and forty-four blue plaques scored positive after the second plating. The mutant frequencies for PL P190BCR-ABL/BB and normal/BB mice were 9.53 × 10 −5 and 4.4 × 10 −5 in kidneys, and 7.2 × 10 −5 and 3.17 × 10 −5 in spleens ( Table 1 ). The 2.2-and 2.3-fold increase in mutant frequencies in PL P190BCR-ABL/BB kidneys and spleens compared to tissue from normal/BB mice was of statistical significance (P = 0.035 in spleen and P = 0.05 in kidneys) (Figure 1 ). The combined mutant frequencies for PL P190BCR-ABL/BB and normal/BB mice were 8.4 × 10 −5 and 3.8 × 10 −5 ( Figure 1 ). The mutation spectrum from mutant plaques was determined by sequencing the whole lacI gene and the lacZ operator (1.2 kb) in the shuttle vector from a sample of blue mutant plaques obtained from PL P190BCR-ABL/BB spleens and kidneys. The dominant mutation in PL P190BCR-ABL/BB spleens and kidneys was G:C → A:T transitions at CpG dinucleotides ( Table 2) . We compared the profile of LacI mutations and their positions to that obtained after treating BB mice with known carcinogens and mutagens. We found that the profile we obtained from P190BCR-ABL/BB mice mostly resembles spontaneous mutations in the lacI gene of Big Blue transgenic mice. We compared the distribution of the positions of those mutations in lacI with the positions of lacI spontaneous mutations in Big Blue mice and found no statistical difference (P = 0.211) 14 (Table 2 ). There was no bias towards a specific lacI position, neither was a unique mutation found in all the P190BCR-ABL/BB mutants analyzed as all mutations were previously reported. Our data suggest that the expression of BCR-ABL in this leukemia mouse model results in an increase in basal spontaneous mutation level.
The P190 bcr-abl transgene is expressed from a truncated mouse metallothionein promoter and is expressed in all cells at a low level in the absence of heavy metals. 1 A high level of P190BCR-ABL driven from the bcr promoter was found to be embryonically lethal. Expression of the transgene was found at different stages of development. 15 Prolonged expression was detected in most tissues including brain, muscle, spleen, and kidney. Compared to the level of expression in tumor samples (lymphoma/leukemia), the relative level of P190BCR-ABL expression is 50-fold lower in brain and 100-fold lower in spleen and kidney. 15 This low level of expression is however sufficient to induce leukemia. We suggest that the transgenic mouse model that we use here is ideal to investigate the early events in BCR-ABL leukemogenesis.
Multistage carcinogenesis appears to require a mutator phenotype. Such a model can explain the high mutation rates encountered in human cancer cells and which spontaneous mutation rates in normal cells cannot account for. 16 It is estimated that the background somatic mutation rate is 1.4 × 10 −10 mutation/base pair/cell which can account for a maximum of two or three mutations in each tumor and not the much larger number that is observed. 17 The relevance of a possible BCR-ABL-induced mutator phenotype in the progression of Ph-positive leukemia is supported by a number of observations. The expression of BCR- pfu, plaque-forming units; PL, pre-leukemic.
Figure 1
Mutant frequencies in kidney and spleen tissue from P190BCR-ABL/Big Blue and normal/Big Blue mice. Genomic DNA was extracted from kidneys and spleens of P190BCR-ABL/Big Blue (P190/BB), as well as from normal/Big Blue (Nor/BB) mice, lambda-LIZ shuttles were recovered and used to infect E. coli lawns in the presence of X-gal. Mutant frequencies are calculated for each sample by enumerating blue mutant plaques relative to the total number of plaques plated. Each data point represents an average of three (kidney) or four (spleen) different mice. Also shown are the combined (Comb) spleen and kidney mutant frequencies from both groups of mice. Nor/BB mice were generated by crossing Big Blue mice (C57BL/6) to the genetic background (F1 C57BLxCBA) of the P190BCR-ABL transgenic mice.
Leukemia ABL seems to be the sole important and consistent cytogenetic event in the chronic phase of CML. 18 Patients in the chronic phase of CML have a higher chance of acquiring acute leukemia compared to normal individuals developing the same disease. 19 Transition to the acute phase of the disease is associated with genetic and cytogenetic aberrations suggesting that the expression of BCR-ABL results in the accumulation of secondary abnormalities. 8 Direct evidence, at the nucleotide level, linking BCR-ABLinduced genomic instability to the abrogation of DNA repair capabilities is starting to emerge. Recently, a 3-to 5-fold increase in spontaneous mutation frequency at the Na-KATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci was observed in Ba/F3 cell lines transfected with P190 and P210 bcr-abl oncogenes. 20 This was accompanied by an increase in expression and activity of DNA polymerase ␤, the least accurate of all DNA polymerases. 20 Also, and in primary hematopoietic cells from newly diagnosed Ph-positive patients, a constitutively activated protease activity that cleaves replication factor C (RFCp140) was observed. 21 This results in the separation of the RFCp140 DNA binding domain from its regulatory domain leading to the abrogation of RFC-dependent DNA repair.
We have shown, using a sensitive in vivo system, an increase in mutant frequency associated with the expression of BCR-ABL at a level relevant for disease induction in a mouse model. We utilized a P190BCR-ABL leukemia mouse model and show an increase in mutant frequencies in both spleens and kidneys before the onset of disease. The mutation spectrum observed suggests that the expression of BCR-ABL results in the increase of basal spontaneous mutation levels. We propose that this phenotype facilitates the accumulation of somatic mutations and thus the progression of Ph-positive leukemia towards a fatal transformed disease. The lack of kidney-related tumors in P190BCR-ABL mice suggests that the mutator phenotype observed in kidney cells is not sufficient for oncogenicity by BCR-ABL and that additional cell specific factor(s) are required. We propose that the P190BCR-ABL/BB mouse is a useful model to investigate genomic instability associated with BCR-ABL expression. This mouse model can be beneficial in assaying the potential therapeutic effect of different tyrosine kinase inhibitors in reversing the mutator phenotype observed with BCR-ABL expression. Data from three P190BCR-ABL mice. The entire lacl gene and the lacZ operator were sequenced from a sample of mutant plaques and compared to spontaneous mutations reported in the Big Blue mouse mutagenesis system. This control data is of spontaneous mutations in lacl from Big Blue mice compiled in lacl data base and software (MutaBase Software, Neal Cariello).
